Humana Inc: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on Apr 27, 2022 and accepted by EDGAR at Apr 27, 2022, 14:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-01-01 to 2022-03-31 | $23.97bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2022-01-01 to 2022-03-31 | $2.89bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-01-01 to 2022-03-31 | $1.29bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-01-01 to 2022-03-31 | $90.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-01-01 to 2022-03-31 | $286.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-03-31 | $930.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-01-01 to 2022-03-31 | $7.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-01-01 to 2022-03-31 | $7.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-01-01 to 2022-03-31 | 127,474,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | $302.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-03-31 | $295.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2022-01-01 to 2022-03-31 | $91.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2022-01-01 to 2022-03-31 | $1.02bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-03-31 | $4.86bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $26.84bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $46.31bn | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $17.53bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-03-31 | $30.97bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-03-31 | $11.29bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-03-31 | $1.69bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2022-03-31 | $15.34bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
| Shares outstanding | At period end2022-03-31 | 126,493,402 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-22-000032. Last ingested by Listed: Nov 6, 2026, 14:15 ET. Listed shows no prices and gives no investment advice.